Medical network - on January 9, in recent years, along with our country population ages, the stroke drugs market expansion. , according to kang CMH monitoring data in 2015 the overall scale of China's stroke drug market is 122.9 billion yuan, a year-on-year growth of 4.6% for the year of 2014. Estimated 2016 annual market size of 2016 yuan, the growth rate of 5.4%.
Commonly known as stroke, stroke is divided into two categories, cerebral thrombosis and cerebral hemorrhage, and has a high incidence and high morbidity, high mortality rate, high recurrence rate of "four high" characteristics of the medical profession it with coronary heart disease, cancer and listed as one of three big disease threat to human health, develops in the elderly. According to the latest release of 2016 cerebral apoplexy epidemiological report, currently there are 70 million stroke patients in our country, the new stroke 2 million people a year, stroke deaths, 1.65 million people a year, and survival in patients with about three-quarters have varying degrees of disability, as the population ages, the disease population will grow.
Stroke medicine market has more than one hundred billion
The rise in incidence and JiuZhenLv driving stroke class medicine market continues to grow. , according to kang CMH monitoring data in 2015 the overall scale of China's stroke drug market is 122.9 billion yuan, a year-on-year growth of 4.6% for the year of 2014. Estimated 2016 annual market size of 129.5 billion yuan, growth rate of 5.4%, visible stroke drugs huge market capacity.
Units: one hundred million yuan
Stroke drugs market share three points
According to kang CMH monitoring data show that in stroke medicine market proportion is the largest, chemical medicine with a market share of 40.9% in 2015, is expected to rise to 43.8% in 2016. Stroke proprietary Chinese medicine, injection, and occupy larger proportion, and traditional Chinese medicine injection is the key of the auxiliary medicine new monitoring objects, and restrict the use of objects, affected by the policy is expected to stroke proprietary Chinese medicine market share will decline by 38.3% in 2015 to 34.5% in 2016.
Stroke drugs market analysis of chemical medicine
Stroke of chemical medicinal drugs in the market, clopidogrel and olathe status obvious advantages, or more than thirty percent of the market of chemical medicine market. Clopidogrel is a kind of ADP receptor blockers, it by blocking the ADP receptors, inhibit the platelet aggregation function to reduce the incidence of disease of heart head blood-vessel. By the French sanofi - fort SAN Della pharmaceutical companies to develop and produce wave vertical dimension, is a product leader, occupies the proportion of 70%; Domestic brands mainly includes the clopidogrel bisulfate tablet (shenzhen xinli Thai) and clopidogrel bisulfate tablet company (Germany), etc.
Olathe neurons for medicine, for brain injury and cause the loss of nerve function, memory and intelligence disorder treatment. This product, who believed in guangdong pharmaceutical times of qing dynasty, astrology than most, above 40%; The second is Harbin European orchid with triple pharmaceutical co., LTD., with the proportion of 28%. In addition, Harbin pharmaceutical group olathe temple injection and capsule combined account for more than 20%.
Stroke drugs market analysis of proprietary Chinese medicine
Stroke proprietary Chinese medicine market, the product concentration is slightly higher than that of chemical medicine market, and give priority to with Chinese medicine, products imported drugs. Blood through the top spot, its chief function is qi and remove stasis, pulse adjustable, inhibit platelet aggregation and increase cerebral blood flow. Injection of blood plug (kunming group) and injection of blood plug (heilongjiang treasured island) is the product of the main representative, both accounts for more than sixty percent of market share. Blood flux agent of arteries and veins thrombosis was monopolized by the guangxi wuzhou pharmaceutical altitude, containing more than 95% market share, make few other manufacturers, but because of the influence of auxiliary limited drug policy, its market share in 2016 is expected to a downward trend; Treasures of Harbin pharmaceutical co., LTD. Of thrombosis capsule, currently less than 1%, but growth momentum.
Stroke drugs market analysis of biological products
Biological products market concentration is very high, in the first four products combined share by more than 90%. Ranking the top four hexose single sialic acid ganglioside sodium, share close to 40%, the calf blood to protein extract proportion, followed by more than 25% of the market.
Single sialic acid four hexose ganglioside can promote a variety of reasons cause the functional recovery of the central nervous system damage, mainly used in the central nervous system traumatic or vascular lesions, such as brain injury, spinal cord injury, ischemic and hemorrhagic cerebrovascular accident and the treatment of Parkinson's disease. The introduction of foreign brands in China have Argentina TRB ShiJie for Europe and Brazil the reshaping of the drug, but for now, both accounts for less than 5%. By qilu pharmaceutical development and production of domestic brands ShenJie (single sialic acid four hexose ganglioside sodium injection) and ShenJie (single sialic acid for injection four hexose ganglioside sodium) or of single sialic acid four hexose ganglioside sodium for half of the market. Other major domestic enterprises include Harbin university, changchun xiang tong pharmaceutical co., Beijing pharmaceutical co., Beijing sihuan pharmaceutical, jilin biomedical engineers as well as the tai chi group and so on. More enterprises to enter, intensified market competition, qilu pharmaceutical held dominance, but its market share slightly declining trend.
Calf blood protein extracts market, fosun group with more than sixty percent of the market share held, Harbin SAN tai biological pharmaceutical co., LTD. And the heilongjiang river pharmaceutical co., LTD., which owns more than 10% of the market share, still need to send the rest of the manufacturer.
|
